Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay

Virology Journal

Volumn 5, Issue , 2008, Pages

  Eichelberger, Maryna C ^a,c   Hassantoufighi, Arash ^a   Wu, Meng ^b   Li, Min ^b  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OVRR   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; GENE PRODUCT; INOSINATE DEHYDROGENASE; MALEIMIDE DERIVATIVE; PROTEIN KINASE C; RIBAVIRIN; VIRUS SIALIDASE; ZANAMIVIR; ANTIVIRUS AGENT; ENZYME INHIBITOR; SIALIDASE; VIRUS PROTEIN;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN; DIAGNOSTIC ACCURACY; ENZYME ACTIVITY; ENZYME ASSAY; HIGH THROUGHPUT SCREENING; IC 50; INFLUENZA; NONHUMAN; SCREENING TEST; VIRUS INHIBITION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; WILD TYPE; ANIMAL; ANTIVIRAL RESISTANCE; CHICK EMBRYO; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; DUCK; ENZYMOLOGY; GENETICS; HUMAN; INFLUENZA VIRUS A; INFLUENZA VIRUS B; METABOLISM; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CHICK EMBRYO; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, VIRAL; DUCKS; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; NEURAMINIDASE; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 53649110260     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-5-109     Document Type: Article

References (32)

1. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. NH Arden PA Patriarca AP Kendal, Options for the control of influenza Alan R. Liss, Inc., New York 1986 155 168
2. Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. WA Keitel TR Cate RL Atmar CS Turner D Nino CM Dukes HR Six RB Couch, Clin Diagn Lab Immunol 1996 3 507 10 8877126
3. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. JA Englund EB Walter A Gbadebo AS Monto Y Zhu KM Neuzil, Pediatrics 2006 118 579 85 10.1542/peds.2006-0201 16950949
4. Potential impact of antiviral drug use during influenza pandemic. R Gani H Hughes D Fleming T Griffin J Medlock S Leach, Emerg Infect Dis 2005 11 1355 62 16229762
5. th century. ED Kilbourne, Emerg Infect Dis 2006 12 9 14 16494710
6. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. RA Bright MJ Medina X Xu G Perez-Oronoz TR Wallis XM Davis L Povinelli NJ Cox AI Klimov, Lancet 2005 366 1175 81 10.1016/S0140-6736(05)67338-2 16198766
7. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. VM Deyde X Xu RA Bright M Shaw CB Smith Y Zhang Y Shu LV Gubareva NJ Cox AI Klimov, J Infect Dis 2007 196 249 57 10.1086/518936 17570112
8. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. AC Hurt P Selleck N Komadina R Shaw L Brown IG Barr, Antiviral Res 2007 73 228 31 10.1016/j.antiviral.2006.10. 004 17112602
9. Reduced sensitivity of influenza A to oseltamivir. JL McKimm-Breschkin PW Selleck TB Usman MA Johnson, Emerg Infect Dis 2007 13 1354 57 18252107
10. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. M-A Rameix-Welti V Enouf F Cuvelier P Jeannin S van der Werf, PLoS Pathog 2008 4 7 1 5 10.1371/journal.ppat.1000103 18654625
11. Oseltamivir and delirious behavior in children with influenza. A Okumura T Kubota T Kato T Morishima, Pediatr Infect Dis J 2006 25 572 16732168
12. Oseltamivir-induced delirium in a geriatric patient. I Kohen, Int J Geriatr Psychiatry 2007 22 935 6 10.1002/gps.1838 17721896
13. Strategies of development of antiviral agents directed against influenza virus replication. HP Hsieh JT Hsu, Curr Pharm Des 2007 13 3531 42 10.2174/138161207782794248 18220789
14. An influenza virus replicon system in yeast identified Tat-SF-1 as a stimulatory host factor for viral RNA synthesis. T Naito Y Kiyasu K Suglyama A Kimura R Nakano A Matsukage K Nagata, PNAS 2007 104 18235 40 17991777 10.1073/pnas.0705856104
15. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. P Palese K Tobita M Ueda RW Compans, Virology 1974 61 397 410 10.1016/0042-6822(74)90276-1 4472498
16. Neuraminidase activity assays for monitoring MDCK cell culture derived influenza virus. DP Nayak U Reichl, J Virol Methods 2004 122 9 15 10.1016/j.jviromet.2004.07.005 15488615
17. A chromogenic substrate for the investigation of neuraminidases. H Tuppy P Palese, FEBS Lett 1969 3 72 75 10.1016/0014-5793(69)80100-6 11946972
18. Applications of a synthetic neuraminidase substrate. P Palese D Bucher ED Kilbourne, Appl Microbiol 1973 25 195 201 4121031
19. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl- alpha-D-N-acetylneuraminate) substrate. M Potier L Mameli M Bélisle L Dallaire SB Melançon, Anal Biochem 1979 94 287 96 10.1016/0003-2697(79) 90362-2 464297
20. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. LV Gubareva RG Webster FG Hayden, Antivir Res 2002 53 47 61 10.1016/S0166-3542(01)00192-9 11684315
21. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. JH Zhang TD Chung KR Oldenburg, J Biomol Screen 1999 4 67 73 10.1177/108705719900400206 10838414
22. Influenza virus M2 protein has ion channel activity. LH Pinto LJ Holsinger RA Lamb, Cell 1992 69 517 28 10.1016/0092-8674(92)90452-I 1374685
23. Rational design of potent sialidase-based inhibitors of influenza virus replication. M von Itzstein WY Wu GB Kok MS Pegg JC Dyason B Jin TV Phan ML Smythe HF White SW Oliver PM Colman JN Varghese DM Ryan JM Woods RC Bethell VJ Hotham JM Cameron CR Penn, Nature 1993 363 418 423 10.1038/363418a0 8502295
24. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. TG Sheu VM Deyde M Okomo-Adhiambo RJ Garten X Xu RA Bright EN Butler TR Wallis AI Klimov LV Gubareva, Antimicrob Agents Chemother 2008 52 3284 92 10.1128/AAC.00555-08 18625765
25. Broad-spectrum antiviral activity of virazole: 1-β-d-ribofuranosyl- 1,2,4-triazole-3-carboxamide. RW Sidwell JH Huffman GP Khare LB Allen JT Witkowski RK Robins, Science 1972 177 705 706 10.1126/science.177.4050.705 4340949
26. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. W Markland TJ McQuaid J Jain AD Kwong, Antimicrob Agents Chemother 2000 44 859 66 10722482 10.1128/AAC.44.4.859-866.2000
27. Membrane accumulation of influenza A virus hemagglutinin triggers nuclear export of the viral genome via protein kinase Calpha-mediated activation of ERK signaling. H Marjuki MI Alam C Ehrhardt R Wagner O Planz HD Klenk S Ludwig S Pleschka, J Biol Chem 2006 281 16707 15 10.1074/jbc.M510233200 16608852
28. In vitro and in vivo influenza virus-inhibitory effects of viramidine. RW Sidwell KW Bailey MH Wong DL Barnard DF Smee, Antiviral Res 2005 68 10 7 10.1016/j.antiviral.2005.06.003 16087250
29. Ribavirin: an antiviral agent. RW Sidwell RK Robins IW Hillyard, Pharmacol Ther 1979 6 123 46 10.1016/0163-7258(79)90058-5 390559
30. Ringing the alarm bells: signaling and apoptosis in influenza virus infected cells. S Ludwig S Pleschka O Planz T Wolff, Cell Microbiol 2006 8 375 86 10.1111/j.1462-5822.2005.00678.x 16469051
31. Signalling events employed in the hypertonic activation of cation channels in HeLa cells. F Wehner T Numata M Subramanyan N Takahashi Y Okada, Cell Physiol Biochem 2007 20 75 82 17595517
32. The cotton rat provides a useful small-animal model for the study of influenza virus pathogenesis. MG Ottolini JCG Blanco MC Eichelberger DD Porter L Pletneva JY Richardson GA Prince, J Gen Virol 2005 86 2823 30 10.1099/vir.0.81145-0 16186238